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1 Introduction
While catalysis refers to the application of chemical cata-
lysts for the acceleration of chemical reactions, biocatalysis 
is the application of natural catalysts (enzymes) instead of 
chemical catalysts. Enzymes offer distinct advantages in the 
realm of industrial application, mainly due to their ability 
to perform highly stereoselective reactions while operating 
under mild reaction conditions, such as ambient tempera-
tures, atmospheric pressure, and neutral pH values, mak-
ing biocatalysis a viable choice for industrial application in 
organic synthesis. Moreover, the application of enzymes is 
aligned with the principles of Green Chemistry guiding the 
chemical industry in the last few decades.1–6
The application of enzymes for industrial purposes has a 
very storied history which has steadily grown from the days 
of Louis Pasteur (1857), who isolated a specific racemate 
with the help of fermentation by various microorganisms.7 
Since then, enzymes have been isolated, mass-produced, 
and re-engineered to fit almost any chemical reaction by 
the application of highly complex protein engineering tech-
niques, like directed evolution8–10 and in silico or de novo 
enzyme design.11,12 While chemical catalysis with various 
metal catalysts is still prevalent in industrial organic syn-
thesis,13–15 it shows its own drawbacks in the form of high 
market price and limited availability of required precious 
metals, like rhodium and palladium,16 along with multiple 
protection and de-protection steps that make the process 
economically unfeasible, and may result in the production 
of large amounts of dangerous or toxic waste.17,18 Those 
drawbacks are especially noticeable in the pharmaceutical 
industry, which is known for its long and rigorous drug de-
sign and production times.19 Thus, enzyme-catalysed pro-
cesses represent a more feasible, economically beneficial, 
and environmentally safer alternative for the pharmaceuti-
cal industry. Truppo20 has shown metrics of rapidly increas-
ing publications and patents discussing “pharmaceutical 
biocatalysis” from 1985 onwards, to which we have added 
the period from 2015 to 2019, shown in Fig. 1, that can 
arguably be correlated to increased testing and usage of 
biocatalytic processes in the pharmaceutical industry.
















Fig. 1 – Number of publications and patents discussing “phar-
maceutical biocatalysis” in the last 35 years. Metrics are 
taken from Google Scholar.
Slika 1 – Broj objavljenih publikacija i patenata na temu farmace-
utske biokatalize u posljednjih 35 godina. Mjerni podat-
ci preuzeti s Google Znalca. 
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The main challenge in the pharmaceutical industry, regard-
ing the production of highly functionalized building blocks, 
is the complexity of molecules and the number of chiral 
centres needed to be produced.21,22 Chiral pharmaceutical 
compounds are usually manufactured in a single enantio-
meric form,22,23 since the opposite enantiomer may have 
adverse effects.23 For the production of chiral drug inter-
mediates, different routes are employed,24 but the applica-
tion and implementation of enzyme-based processes and 
their use in the pharmaceutical industry has shown great 
promise, since enzymes inherently satisfy the requirements 
expected for the drug production. Hence, several phar-
maceutical companies are now outsourcing the synthetic 
stages to focus on discovery and formulation.23
2 Biocatalytic process development
Although running biochemical reactions is similar to run-
ning chemical reactions, it requires additional multidisci-
plinary skills, such as from biology and biochemistry, along 
with chemical and engineering sciences that are essential 
features of biochemical engineering.25 The pharmaceutical 
processes are run on a smaller scale compared to chemical 
processes. For biocatalysis to be run on an industrial scale, 
compared to the academic research, the process requires 
significant substrate concentrations. With respect to bio-
catalyst usage, conversion, and optical purity, some general 
rules of thumb for a feasible enzyme-catalysed process can 
be roughly defined.26–29 The main problem for industrial 
implementation of biocatalysis lies in the transfer of the 
biocatalytic process from laboratory to a larger scale, which 
can cause a loss in productivity and product quality,28 but 
can be overcome by gaining insight into the reaction char-
acteristics on a laboratory scale.22,28 A methodology for de-
velopment of a biocatalytic process is outlined in Fig. 2.
Naturally occurring enzymes, whether in isolated or whole 
cell form, often exhibit challenges regarding their applica-
tion in relation with their stability, activity, and re-usability, 
especially when scaled-up from a laboratory to industrial 
scale.21 There is a multitude of ways to minimize or even 
overcome those disadvantages. Biocatalyst engineering 
approach usually includes different types of enzyme im-
mobilization and various protein engineering techniques. 
Of those two, the protein engineering technique currently 
seems to relish main focus largely due to its practical feasi-
bility and speed of development, despite the increasingly 
growing possibility for combining the immobilization pro-
cedures with enzyme engineering techniques into one effi-
cient solution.30–33 In order to develop the optimal biocat-
alytic process, it is important to examine kinetic properties 
of enzymes in detail by integrating enzyme reaction kinet-
ics and mass balance in the reactor.34 The precondition for 
an effective scale-up of processes is the speed of develop-
ment, which can be achieved by the use of miniaturized 
experimentation or mathematical modelling.34 Mathemat-
ical modelling can be useful in finding the most cost-effec-
tive mode for the bioprocess on an industrial level.
3 Statins and statin precursors
A lucrative aspect27,35–40 of the application of enzymes in 
the pharmaceutical industry is in the production of statin 
precursors. Namely, statins are hypolipidemics, a medica-
tion used for lowering LDL cholesterol (LDL-C) in blood, 
and for prevention of cardiovascular morbidity and mortal-
ity.27,41–44 Besides lowering the LDL-C levels, and therefore 
reducing cardiovascular risk,45 it has been reported that the 
use of statins has additional positive side effects.46,47 Statins 
act as competitive inhibitors of HMG-CoA reductase, a key 
enzyme involved in cholesterol biosynthesis,27,44,47–51 and 
therefore are one of the most prescribed drugs today.27,52 
Presently, there are a number of statins on the market, be-
ing either natural or synthetic products,35 and all having in 
common the pharmacophore syn-3,5-dihydroxy carboxy-
late side-chain.50 For the industrial production of statins, 
the chemical route is employed, which is a time-consum-
ing, multi-step chemical process that can occur at very 
severe conditions.28,35,53–57 Moreover, the two chiral cen-
tres present in the molecule are challenging to make by 
applying traditional chemical methods.50,55 The increasing 
commercial demand for statins, and the need for simple 
preparation on the industrial scale, have led to immense 
efforts towards finding a more efficient and economical 
production of statin side chains.28,29,38,51,58,59
4 Biocatalysis as a response to the 
challenges arising from chemical 
synthesis of statin precursors 
Driven by the requirements of high chemical and stereo-
chemical purity, a variety of biocatalytic routes, involving 
different classes of enzymes and starting materials, have 
been developed for their enantioselective synthesis,27,55 
since enzymes inherently circumvent the challenges arising 
from the chemical synthesis.60 Thus, some pharmaceuti-












Fig. 2 – Methodology for the development of a biocatalytic process
Slika 2 – Metodologija razvoja biokatalitičkog procesa
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Pfizer, Bristol-Myers Squibb, Diversa Corporation, Dow 
Pharmaceutical Sciences, DSM Pharma Chemicals, Lek 
Pharmaceuticals, IMI TAMI (Institute for Research and De-
velopment Ltd.),61 among others, have shifted their focus 
towards applying biochemical catalysis for the production 
of statin intermediates.
The most common biocatalytic methods towards the pro-
duction of statin intermediates27,29,38,39,50,62 can be broadly 
grouped into two strategies36,55 (Fig. 3).
The first strategy (Fig. 3a), which encompasses most biocat-
alytic methods, involves the synthesis of the key chiral pre-
cursor, ethyl (R)-4-cyano-3-hydroxybutyrate, on which the 
second stereocentre is introduced at a later step. Most of 
the biocatalytic methods fall under this strategy,55 although, 
according to some literature, the usage of nitrilases is clas-
sified as a separate third strategy.37,38 The second strategy 
(Fig. 3b) involves the generation of both chiral centres in 
a single step using aldolases, which catalyse the aldol re-
action that results with a more advanced six-carbon statin 
side-chain.36,55 This strategy is often expanded by coupling 
aldolases with oxidoreductases and/or halohydrin dehal-
ogenases, as possible enzyme combination,27,36,55 to pro-
duce the key statin precursor.
Although different biocatalytic approaches have been de-
veloped, ever-growing attention is being shifted towards a 
simplified process containing fewer reaction steps with a 
high atom economy, in which the generation of both chiral 
centres is done in a single step using the deoxyribose-phos-
phate aldolase (DERA).28,35,67,48,51,54,58,63–66 By using achiral 
substrates28,48 the DERA enzyme catalyses the sequential al-
dol addition, which results in an enantiomerically pure lac-
tol, a cyclized 2,4,6-trideoxyhexose,27,68–72 which is a valu-
able chiral synthon40,64,69 used for the production of statin 
intermediates.40,64,67,68,70,73–75 Although the application of 
the DERA enzyme shows great potential in the production 
of statin intermediates, the enzyme demonstrates some 
major drawbacks for its practical application,27,40,44,48,58,59 
but due to the high interest in its application, the en-
zyme is being continuously re-engineered to have a better 
fit.38,55,58,65,69,72 The DERA-based strategy is almost by de-
fault coupled with an oxidation step, in which the lactol is 
further oxidized into a lactone, such as cyclized 3,5-dihy-
droxyhexanoic acid, which is a more stable form of lactol76 
and thus presents a key product in the synthesis of sta-
tin intermediates.27,36,38,50,54,72,73 The significance of those 
two reactions is evident also in the industry: DSM Pharma 
Chemicals77,78 and Diversa Corporation40 operate the DE-
RA-catalysed aldol reaction followed by chemical oxida-
tion of the produced lactol27,39,40,77,78, while Lek Pharma-
ceuticals patented the DERA-catalysed reaction followed 
by oxidation catalysed by dehydrogenases (DHs), which 
results in a more economic process: reduced number of 
synthetic steps, improved and simplified reaction, etc.59 By 
studying the available literature, it is evident that there are 
only a few known suitable ways for chemical oxidation of 
the enzymatically produced lactol,40,51,54,65 whereas investi-
gations on the enzymatic lactol oxidations remain rare.38,51 
This is especially interesting considering that the chemical 
oxidation of the DERA-produced lactols is done with the 
excess of harsh chemicals, while the biocatalytic oxidation 
uses oxygen as a co-substrate and produces water as a 
by-product, which classifies the latter approach in the area 
of green chemistry.38 Based on the accessible literature, 
an interesting route towards statin side-chain intermedi-
ate production seems to be a multi-enzyme process con-
sisting of DHs and halohydrin dehalogenases (HHDHs), 
where the HHDHs are used for their ability to replace the 
halide group with a strong nucleophile containing nitro-
gen,36,62,79,80 such as nitrile62 (Fig. 4). 
A similar reaction of statin intermediate synthesis was pat-
ented by Codexis, who demonstrated a two-step three-en-
zyme catalysed reaction involving two DHs, where one is 
responsible for the substrate oxidation, and the other for 
a)
b)
Fig. 3 – Biocatalytic strategies towards the production of statin side-chain intermediates. a) The first strategy results in the formation 
of ethyl (R)-4-cyano-3-hydroxybutyrate,36,55 while b) the second strategy is based on an aldol reaction that results in the for-
mation of a six-carbon intermediate.54,55 
Slika 3 – Biokatalitički načini proizvodnje prekursora bočnog lanca statina. Prvi pristup (a) rezultira nastankom etil-(R)-4-cijano-3-hi-
droksibutanoat,36,55 dok se drugi pristup (b) temelji na dvostrukoj aldolnoj adiciji kojom nastaje dihidroksi aldehid sa šest 
C-atoma.54,55
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coenzyme regeneration, and an HHDH enzyme applied 
for the dehalogenation reaction and cyano-group addi-
tion.81 They filed a new successive patent, in which they 
expanded the substrate scope and applied newly engi-
neered enzymes.82 Akin reactions were claimed by DSM 
Pharma Chemicals, who are using HHDH enzymes to syn-
thesize epoxides, lactones, alcohols, and other intermedi-
ates in the preparation of active pharmaceutical ingredi-
ents (APIs), in particular statins.83 In their patent, they also 
claim a completely chemoenzymatic pathway towards the 
production of the desired lactone by combining DERA and 
HHDH enzymes.
5 Multi-enzyme systems and reaction 
engineering for the production  
of statin precursors
The application of multi-enzyme (cascade) systems shows a 
promising direction to produce optically active chemicals. 
That way, the process results in higher yields, spends few-
er chemicals, and saves time, especially when an unstable 
intermediate needs not be isolated. Moreover, the process 
conducted in this manner leads to a significant reduction in 
both waste and production costs on the industrial scale.45 
The main drawback, which can be overcome by applying 
mathematical modelling, is finding optimal process con-
ditions. Therefore, when finding the most cost-effective 
mode for statin side-chain biosynthesis, especially for fur-
ther industrial use, it is of great importance to understand 
the mechanisms and kinetics of the enzyme systems.46 For 
this purpose, mathematical modelling, as reaction engi-
neering tool, is used and has an important role in the study 
of enzymatic reactions.46 Despite its undeniable impor-
tance for each of the synthetic steps towards the produc-
tion of statin precursors, the available literature offers very 
little or virtually no kinetic data obtained based on kinetic 
models. The data concerning aldolase-catalysed reactions 
is scarce53,84,85, and for now, only two research papers re-
port mathematical modelling of the reaction towards statin 
side-chain production.53,86 Švarc et al.86 have reported a 
mathematical model (consisting of a formal kinetic model 
that includes the data-driven or the empirical model that 
has less kinetic constants) validated in multiple reactor 
configurations. Using the developed model, process sim-
ulations were done and optimal process design was pro-
posed. Ručigaj and Krajnc53 have reported a very complex 
model for the sequential aldol reaction with different sub-
strates catalysed by crude DERA expressing culture lysate. 
Regarding reactions catalysed by NAD(P)-dependent DHs, 
for now, only two published research articles offer kinetic 
data on the enzymes used for oxidation of the DERA-pro-
duced lactols, but without further model development that 
would help in process optimization and scale-up. The first 
research was published in 2014,51 in which the kinetic data 
of E. coli membrane-bound PQQ-dependent glucose de-
hydrogenase (GDH) was given. The authors employed a 
DERA-GDH coupled system using a whole-cell catalyst, 
but despite performing successful oxidation mediated by 
the PQQ-GDHs, the system resulted in a disadvantageous 
industrial application, due to the application of the PQQ as 
a cofactor and the low expression level of GDHs as mem-
brane protein. This finding was followed by the research 
of Xu group in 201638, who carried out oxidation of the 
key lactol using a novel NADP-dependent aldehyde dehy-
drogenase (AlDH). Although they published values of ki-
netic parameters, they had not developed a mathematical 
model that would provide a basis for future application. In 
addition to the apparent lack of aldolase and DH kinetic 
data, the data related to HHDHs and the reaction of statin 
side-chain production remains unavailable.35,87 It should 
be noted that, for the time being, catalytic data on the 
biocatalytic reaction of epoxide ring-opening in the pres-
ence of strong nucleophiles has yet to be estimated; thus, 
no mathematical models have been developed although 
these phenomena are of scientific interest.27,87–89 Based on 
the previously mentioned research, it is obvious that an en-
gineering aspect regarding development and optimization 
of multi-enzyme-catalysed reactions towards the biocata-
lytical production of statin intermediates is still lacking. 
6 Conclusion 
As we have shown in this review, biocatalysis is very much 
an active field of development in the pharmaceutical in-
dustry, and can still offer many new and beneficial eco-
nomic and environmental advantages. Moreover, it could 
be said that statin precursor production using biocatalysis is 
still in its relatively early stages of development, and shows 
a lot of promise and untapped potential waiting to be ex-
plored and utilized.
Fig. 4 – DH-catalysed oxidation of ethyl 4-chloro-3-oxobutanoate followed by HHDH-catalysed conversion of ethyl (S)-4-chloro-3-hy-
droxybutyrate into ethyl (R)-4-cyano-3-hydroxybutyrate.36,62,79 The change in stereo-configuration from the substrate to the 
final product is caused by a switch in priority of the substituents at the chiral centre according to the Cahn-Ingold-Prelog (CIP) 
priority rules.79
Slika 4 – Reakcija oksidacije etil-4-kloro-3-oksobutanoata katalizirana enzimom DH nakon koje slijedi reakcija biotransformacije 
etil-(S)-4-kloro-3-hidroksibutanoata u etil-(R)-4-cijano-3-hidroksibutanoata katalizirana enzimom HHDH.36,62,79 Promjena u 
RS-konfiguraciji uzrokovana je promjenom prostornog razmještaja atoma na kiralnome centru prema Cahn-Ingold-Prelogo-
vim (CIP) pravilima prednosti.79
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SAŽETAK
Biokataliza u proizvodnji farmaceutskih intermedijara:  
prekursori statina
Anera Švarc, Dino Skendrović i Ana Vrsalović Presečki *
Napredak tehnologije usko je vezan uz primjenu enzima u kemijskoj sintezi. Biokataliza ima velik 
utjecaj na različite industrije a među njima se posebno ističe farmaceutska industrija. Primjena en-
zima pokazuje značajne prednosti u usporedbi s tehnikama klasične kemijske sinteze te se smatra 
i ‘zelenim’ rješenjem. Primjenjujući nove dostupne tehnike i tehnologije, enzime je moguće u pot-
punosti prilagoditi zahtjevima određenog procesa. Danas je poznato nekoliko farmaceutskih tvrtki 
koje uz pomoć enzima uspješno proizvode vrijedne intermedijare za proizvodnju aktivnih farma-
ceutskih spojeva, a u njih se ubrajaju i prekursori statina. Statini su hipolipidemici, lijekovi koji se 
upotrebljavaju za prevenciju kardiovaskularnih bolesti te za snižavanje koncentracije kolesterola 
u krvi. Metoda klasične kemijske sinteze intermedijara statina vrlo je zahtjevna te stoga njihova 
proizvodnja primjenom enzimski kataliziranih reakcija ima značajne prednosti. Iz tog razloga za 
proizvodnju intermedijara statina istraživanje i razvoj uz primjenu reakcijskog inženjerstva sve se 
više usmjeravaju prema primjeni biokatalize.
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Enzimi, biokataliza, zelena kemija, intermedijari, farmaceutska industrija, statini
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